BriaCell says patient achieves sustained complete resolution of lung metastasis

BriaCell (BCTX) Therapeutics announced the sustained complete resolution of lung metastasis in a patient with hormone receptor-positive, HER2-negative, metastatic breast cancer treated with Bria-OTS, the Company’s personalized off the shelf immunotherapy. BriaCell’s first Bria-OTS study patient, a 78-year-old woman with advanced disease and multiple prior treatment failures, achieved 100% resolution of a lung metastasis following four doses of BriaCell’s Bria-OTS monotherapy. The complete response was first observed at two months and confirmed at four and now six months. The patient has been dosed with 12 cycles of Bria-OTS to date. “These results represent an exciting clinical milestone in the Bria-OTS program,” stated Neal S. Chawla MD, Director at the Sarcoma Oncology Center, Santa Monica, CA, and Principal Investigator for the Bria-OTS study. “We are seeing strong single agent activity in a very challenging population and are eager to explore this approach across more patient subtypes and tumors.”